- D3 (cholecalciferol) raises and maintains blood 25(OH)D levels more effectively than D2 (ergocalciferol) — a meta-analysis of 24 RCTs confirmed higher potency of D3 per equivalent dose (Tripkovic et al., AJCN).
- Correcting deficiency (25(OH)D <20 ng/mL) has clear benefit; broad supplementation in already-replete adults for cancer, cardiovascular events, or major fractures showed no benefit in the 25,871-person VITAL trial or the 5,110-person D-Health trial.
- Higher-risk groups who actually benefit from testing/supplementation: people with limited sun exposure, dark skin at northern latitudes, older adults, those with malabsorption (celiac, IBD, bariatric surgery), and pregnant women.
- Standard adult maintenance dose: 600–800 IU/day (RDA); deficiency correction typically uses 2000–4000 IU/day for 6–12 weeks, then retest. NIH ODS Upper Limit is 4000 IU/day for adults.
- Interactions: reduces effectiveness of statins in some studies at very high doses; increases calcium absorption (relevant with thiazides); can be lowered by anticonvulsants and glucocorticoids.
- Evidence grade: Moderate
Vitamin D is most useful when it corrects a real deficiency: it supports calcium absorption, bone mineralization, and prevention of rickets/osteomalacia, but routine high-dose supplementation has not consistently prevented cancer, cardiovascular disease, depression, diabetes, or fractures in generally healthy adults (NIH Office of Dietary Supplements, VITAL trial, USPSTF evidence review). For supplements, vitamin D3 usually raises blood 25(OH)D better than D2, while calcifediol raises it faster but is closer to a drug-like option and has more pharma-funded evidence (Tripkovic meta-analysis, calcifediol RCT). The safe adult upper limit used by the U.S. National Academies is 4,000 IU/day; toxicity is uncommon at normal doses but can cause hypercalcemia, kidney stones, nausea, weakness, constipation, kidney injury, and dangerous interactions with thiazides, digoxin, high-dose calcium, and some other medicines (NIH Office of Dietary Supplements, National Academies/IOM UL chapter).
Table of Contents
- Evidence summary
- What vitamin D is
- All forms and types of vitamin D
- How vitamin D works
- What works and what does not
- Benefits with evidence grades
- Risks and all side effects
- All interactions
- Who should avoid vitamin D
- Dosage and how to take it
- Independent research, funding, and conflict review
- Frequently asked questions
- Sources
Evidence summary
| Claim | Evidence | Source country | Funding / conflict check | Strength |
|---|---|---|---|---|
| D3 raises 25(OH)D better than D2, especially with bolus dosing. | Systematic review/meta-analysis found D3 significantly more efficacious than D2; daily-dose differences were smaller. | United Kingdom | UK Medical Research Council, Department of Health, BBSRC; no supplement-company funding found in the abstract record. | Strong PubMed |
| Calcifediol raises blood vitamin D faster than cholecalciferol. | Postmenopausal-women RCT: 35.0% on calcifediol vs 8.2% on cholecalciferol reached >30 ng/mL by month 4. | Spain | Supported by Faes Farma; four authors were Faes Farma R&D employees, so the efficacy claim is downgraded for pharma conflict. | Moderate PubMed |
| Vitamin D alone does not reliably prevent fractures in healthy community adults. | USPSTF evidence review of 11 RCTs found no lower fracture incidence in adults without known deficiency, osteoporosis, or prior fracture. | United States | U.S. government/Public Health Service evidence review; no product sponsor. | Strong PubMed |
| Vitamin D plus calcium provides only a small fracture benefit in high-risk older adults and raises stone/renal risk. | Cochrane review: D plus calcium reduced hip fracture risk (RR 0.84) but increased renal disease (RR 1.16) and mild hypercalcemia (RR 2.28). | United Kingdom / international trials | Cochrane review; funding/conflict details not fully visible on summary page, so treated as probably independent but checked against USPSTF. | Strong Cochrane |
| Vitamin D3 2,000 IU/day does not prevent invasive cancer or major cardiovascular events in generally healthy older adults. | VITAL RCT: cancer HR 0.96 and major cardiovascular events HR 0.97 over median 5.3 years. | United States | NIH-funded; study capsules/placebos donated by Pharmavite, Pronova BioPharma, BASF, and testing support from Quest, so product/testing conflicts are disclosed and claim is supported because result was null. | Strong PubMed / PMC full text |
| Vitamin D3 2,000 IU/day does not prevent depression in adults aged 50+. | VITAL-DEP RCT: depression events 12.9 vs 13.3 per 1,000 person-years; HR 0.97. | United States | NIH grants; no direct antidepressant or supplement-company funder found in PubMed record. | Strong PubMed |
| Vitamin D may modestly reduce acute respiratory infections, mainly in deficient people using daily/weekly dosing. | Individual-participant-data meta-analysis: overall NNT 33; NNT 4 in profound deficiency with daily/weekly dosing. | United Kingdom / international trials | NIHR-funded; authors reported no financial relationships with interested organizations. | Moderate BMJ |
| Vitamin D3 4,000 IU/day did not significantly prevent type 2 diabetes in prediabetes not selected for deficiency. | D2d RCT: HR 0.88, 95% CI 0.75–1.04; P=0.12. | United States | NIDDK/NIH Office of Dietary Supplements/American Diabetes Association; no glucose-drug company sponsor identified in PubMed record. | Strong PubMed |
| COVID-19 treatment/prevention evidence remains insufficient for a general recommendation. | Cochrane living review found very uncertain evidence; later meta-analysis in deficient COVID-19 patients reported low-to-moderate quality and non-robust mortality signal. | Germany / China | Cochrane and academic reviews; funding/conflicts incompletely visible in abstract records, so conclusions are conservative. | Weak to moderate Cochrane PubMed / 2025 meta-analysis |
What vitamin D is
Vitamin D is a fat-soluble prohormone, not just a simple vitamin: skin makes vitamin D3 after UVB exposure, foods and supplements provide D2 or D3, the liver converts them to 25-hydroxyvitamin D [25(OH)D or calcifediol], and the kidney and other tissues convert 25(OH)D to the active hormone 1,25-dihydroxyvitamin D [1,25(OH)2D or calcitriol] (NIH Office of Dietary Supplements). The 25(OH)D blood test is the usual status marker because it reflects vitamin D from sun, food, and supplements, while calcitriol can be normal or high even when stores are low (NIH Office of Dietary Supplements).
The active compounds — what actually does the work
D2 and D3 are storage-input forms; calcifediol is the circulating status form; calcitriol is the active hormone that binds the vitamin D receptor and regulates calcium/phosphorus homeostasis, bone mineralization, and many gene-expression pathways (NIH Office of Dietary Supplements). This distinction matters because a D3 capsule, a calcifediol softgel, and prescription calcitriol are not interchangeable: D3 is typical nutritional replacement, calcifediol is faster and more predictable in some malabsorption or liver-conversion contexts, and calcitriol is a prescription active hormone with higher hypercalcemia risk (Calcifediol review, Cochrane mortality review).
All forms and grades
| Form / delivery | What it is | Bioavailability / potency | Best use | Cost / access | Verdict |
|---|---|---|---|---|---|
| D3 / cholecalciferol | Animal-derived or lichen-derived vitamin D form; common in capsules, softgels, tablets, drops, sachets, fortified foods, and injections. | Usually raises 25(OH)D better than D2, especially as bolus dosing; a UK RCT found D3-fortified foods raised 25(OH)D more than D2 in South Asian and White European women (Tripkovic meta-analysis, daily D2 vs D3 RCT). | First-line supplement form for most people with low intake or confirmed deficiency. | Generally cheapest and widely available. | Best default |
| D2 / ergocalciferol | Plant/fungal-derived vitamin D form; used in vegan products and some fortification. | Effective, but often less potent than D3 for raising total 25(OH)D; D2 can raise 25(OH)D2 while lowering measured 25(OH)D3 in some trials (D2/D3 bioavailability RCT). | Vegan supplementation when lichen D3 is unavailable; plant-source fortification contexts. | Often similar or slightly higher cost depending on product. | Works, not preferred |
| Calcifediol / 25(OH)D3 | Pre-hydroxylated vitamin D metabolite, closer to the blood marker measured on tests. | More rapidly absorbed and more potent than cholecalciferol; one review reports about 93% intestinal absorption for calcifediol vs 79% for cholecalciferol, while a pharma-funded RCT found faster target attainment (Calcifediol review, calcifediol RCT). | Clinician-directed correction where rapid, predictable rise is needed, or possible malabsorption/liver conversion issues. | Usually more drug-like and less common than D3 supplements; evidence includes pharma conflicts. | Powerful but medicalized |
| Calcitriol / 1,25(OH)2D | Active vitamin D hormone; prescription drug, not a routine supplement. | Bypasses normal activation control and can raise calcium quickly. | Specific conditions such as chronic kidney disease-related mineral disorders or hypoparathyroidism under medical supervision. | Prescription only. | Not for self-supplementing |
| Liposomal D3 | D3 packaged in lipid vesicles intended to improve dispersion and absorption. | One clinical experiment found faster calcidiol rise than oily formulation, especially in severe deficiency, but the study disclosed company conflicts: two authors were partners and two were employees of Lipid Systems (liposomal D3 study). | Possible option when standard oil-based D3 fails or absorption is a concern. | Usually premium priced. | Promising, conflicted evidence |
| D3 + K2 combination | D3 paired with vitamin K2, usually MK-7, to support vitamin K-dependent proteins such as osteocalcin and matrix Gla protein. | A meta-analysis of 8 RCTs found vitamin K plus D increased total BMD and lowered undercarboxylated osteocalcin, with more favorable effect expected with K2; evidence is stronger for bone markers than hard fracture/CVD outcomes (K+D meta-analysis). | People wanting a bone-health stack when not using warfarin and when diet is low in vitamin K. | More expensive than plain D3. | Optional, not mandatory |
| Capsules / softgels / tablets | Most common oral dose form; often oil-based for fat-soluble D3. | Good when taken with a fat-containing meal; absorption can fall with orlistat, bile acid sequestrants, and fat-malabsorption disorders (NIH Office of Dietary Supplements, drug-vitamin D systematic review). | Daily or weekly maintenance. | Low cost. | Practical default |
| Drops / sprays | Liquid vitamin D, useful for infants, children, older adults, or people who dislike pills. | Can be effective if dose is accurately measured; dosing errors are a known toxicity pathway with concentrated liquids. | Infants and flexible low-dose regimens. | Moderate cost; dosing accuracy varies by dropper. | Useful, measure carefully |
| Injections / high-dose sachets | Large intermittent doses used in medical practice, including some Indian deficiency protocols. | Can correct deficiency but high intermittent boluses have not consistently improved outcomes and may increase falls/fractures in older adults; an India review describes intramuscular D3 protocols but this is medical treatment, not wellness use (India deficiency review, elderly fracture meta-analysis). | Clinician-managed severe deficiency or adherence problems. | . | Avoid DIY megadoses |
Text version of this infographic
| Form | Source | Effect | Best use | Verdict |
|---|---|---|---|---|
| D2 / ergocalciferol | Plant or fungal | Works but is often less potent than D3 for raising 25(OH)D. | Vegan fortification or fallback when D3 is unavailable. | Acceptable fallback. |
| D3 / cholecalciferol | Skin-made, animal-derived, or lichen-derived | Usually raises 25(OH)D better overall. | Most supplement users correcting low vitamin D. | Preferred for most. |
How it works
What the body does with it
Vitamin D improves intestinal absorption of calcium and phosphorus, which is why inadequate vitamin D can impair bone mineralization and cause rickets in children or osteomalacia in adults (NIH Office of Dietary Supplements). The National Academies committee emphasized that vitamin D requirements assume adequate calcium intake and that “no amount of vitamin D is able to compensate for inadequate total calcium intake” (National Academies DRI report).
Why form and delivery matter
D2 and D3 must be absorbed with fat and processed through the liver; calcifediol skips hepatic 25-hydroxylation and therefore gives a faster, more predictable rise; calcitriol bypasses both conversion steps and therefore carries more calcium-related risk (Calcifediol review). Delivery matters because orlistat, cholestyramine, fat malabsorption, and bile-acid disruption can reduce absorption of fat-soluble vitamin D (drug-vitamin D systematic review, Mayo Clinic).
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Bone health / deficiency diseases | WORKS | Vitamin D is essential for calcium absorption and prevention/treatment of rickets and osteomalacia (NIH Office of Dietary Supplements). | Requires adequate calcium; benefits are clearest in deficient people. |
| Fracture prevention in generally healthy community adults | DOESN'T | USPSTF review found vitamin D alone or with calcium was not associated with reduced fracture incidence in adults without known deficiency or osteoporosis (USPSTF evidence review). | Does not apply to diagnosed deficiency, osteoporosis, or institutionalized frail adults. |
| Fracture prevention in high-risk older adults | MIXED | Cochrane found vitamin D alone unlikely to prevent fractures, while vitamin D plus calcium produced a small hip-fracture reduction, especially in institutionalized older adults (Cochrane). | Calcium co-use raises kidney stone/renal and GI adverse-event concerns. |
| Mood / depression prevention | DOESN'T | VITAL-DEP found no significant reduction in depression or clinically relevant depressive symptoms with 2,000 IU/day D3 (VITAL-DEP). | Treat deficiency if present, but do not market D3 as an antidepressant. |
| Immune support / acute respiratory infections | MIXED | BMJ IPD meta-analysis found modest protection overall, strongest in profound deficiency using daily/weekly dosing (BMJ). | Bolus megadoses did not show the same protection. |
| Cancer prevention | DOESN'T | VITAL found 2,000 IU/day D3 did not lower invasive cancer incidence (VITAL). | Cancer mortality signals remain hypothesis-generating, not a prevention claim. |
| Cardiovascular prevention | DOESN'T | VITAL found no reduction in major cardiovascular events (VITAL). | Observational low-D associations do not prove supplements prevent heart disease. |
| Metabolic health / diabetes prevention | DOESN'T | D2d found 4,000 IU/day D3 did not significantly reduce diabetes progression in prediabetes not selected for deficiency (D2d). | Subgroups with true deficiency remain a research question. |
| Mortality | MIXED | Cochrane concluded D3 may reduce mortality, with about 150 adults treated for five years to save one additional life (Cochrane mortality review). | Mostly older populations; not proof that high-normal levels are better. |
| Muscle strength / falls | MIXED | Severe deficiency can cause weakness, but high intermittent dosing in older healthy populations may not help and may increase fracture/fall concerns (elderly fracture meta-analysis, NIH Office of Dietary Supplements). | Avoid large boluses unless prescribed. |
| COVID-19 prevention or treatment | INSUFFICIENT EVIDENCE | Cochrane found very uncertain evidence for COVID-19 treatment, and later deficient-patient meta-analysis reported non-robust mortality signal with no clear ICU/ventilation benefit (Cochrane PubMed, 2025 meta-analysis). | Correct deficiency for general health, but do not use vitamin D as a COVID treatment substitute. |
Text version of this infographic
- Works: deficiency correction, rickets/osteomalacia prevention, calcium absorption.
- Mixed: acute respiratory infections, fracture prevention in high-risk institutionalized older adults when paired with calcium, and mortality.
- Doesn't: broad prevention of cancer, cardiovascular disease, depression, and diabetes in generally healthy or not-deficient populations.
- Insufficient: COVID-19 treatment or prevention claims.
- Rule of thumb: Benefit is more plausible when baseline vitamin D is low, dosing is regular rather than bolus, and the endpoint is bone/mineral physiology.
Benefits by claim
Bone and mineral metabolism — Strong for deficiency correction; mixed for fractures
Vitamin D’s clearest benefit is preventing and treating deficiency states that impair calcium absorption and bone mineralization (NIH Office of Dietary Supplements). The fracture story is narrower: vitamin D alone is unlikely to prevent hip fractures in older adults, while vitamin D plus calcium gives a small benefit mainly in high-risk institutional settings and increases renal and hypercalcemia-related adverse events (Cochrane).
Mood and depression — Strong evidence against broad prevention
The best large trial does not support vitamin D as a depression-prevention supplement: VITAL-DEP found no significant difference in depression incidence or mood-score change with 2,000 IU/day D3 compared with placebo (VITAL-DEP). A low vitamin D result can coexist with depression because illness, indoor lifestyle, obesity, inflammation, or low activity can reduce vitamin D status; that association does not prove that D3 treats depression.
Immune and respiratory infections — Moderate, targeted, not universal
The most credible positive signal is for acute respiratory infections, where an individual-participant-data meta-analysis found modest protection overall and the strongest effect in profound deficiency with daily or weekly dosing (BMJ). This is not a license for high-dose boluses: the same analysis reported better protection without bolus dosing (BMJ).
Cancer, cardiovascular disease, and diabetes — Strong evidence against routine prevention claims
VITAL is the central trial for broad disease prevention: 25,871 participants taking 2,000 IU/day D3 did not have lower invasive cancer or major cardiovascular events over median 5.3 years (VITAL). D2d similarly found 4,000 IU/day D3 did not significantly reduce progression from prediabetes to diabetes in adults not selected for vitamin D insufficiency (D2d).
Mortality — Mixed and dose-status dependent
Cochrane concluded that D3 may reduce mortality, estimating roughly 150 adults treated for five years to save one additional life, but this finding is not the same as proving high-dose vitamin D extends life in healthy people (Cochrane mortality review). The NIH fact sheet also notes that higher serum 25(OH)D ranges have been associated with increased all-cause mortality and other risks in some observational evidence, which is why the “more is better” interpretation is disputed (NIH Office of Dietary Supplements).
Risks and all side effects
Vitamin D toxicity is primarily a calcium problem: excessive vitamin D can cause hypercalcemia, hypercalciuria, kidney stones, soft-tissue/vascular calcification, kidney injury, nausea, vomiting, constipation, weakness, confusion, dehydration, excessive thirst, and abnormal heart rhythm risk (NIH Office of Dietary Supplements, Vitamin D Toxicity clinical review). The National Academies adult upper limit is 100 mcg/day, equal to 4,000 IU/day, for adults and children 9 years and older (NIH Office of Dietary Supplements, IOM/NAM UL chapter).
| Side effect / risk | Frequency | Dose relationship | What to watch for | Evidence |
|---|---|---|---|---|
| Hypercalcemia | Rare at standard doses; serious when present. | Risk rises with excessive dosing, active vitamin D forms, high calcium intake, granulomatous disease, kidney disease, thiazides, or dosing errors. | Nausea, vomiting, constipation, weakness, confusion, thirst, frequent urination, dehydration, arrhythmia risk. | Toxicity usually involves 25(OH)D >150 ng/mL / 375 nmol/L (NIH ODS, toxicity review). |
| Kidney stones / renal events | Uncommon but measurable in large trials with calcium co-use. | Higher with calcium + vitamin D than vitamin D alone, especially with high total calcium. | Flank pain, blood in urine, recurrent stones, high urine calcium. | WHI calcium + D increased stone risk by 17%, and USPSTF review found absolute stone risk increase of 0.33% with combined supplements (NIH ODS, USPSTF evidence review). |
| Nausea, constipation, weakness | Usually uncommon and a sign of high calcium rather than ordinary low-dose D3. | More likely with high-dose vitamin D, high calcium, calcitriol/alfacalcidol, or accidental megadosing. | Stop unsupervised high-dose products and check calcium/25(OH)D if symptoms occur. | Listed as toxicity manifestations of hypercalcemia (NIH ODS). |
| Toxicity from high doses | Rare but potentially life-threatening. | Usually from excessive supplements, prescription errors, concentrated drops, or taking multiple products; 4,000 IU/day is the adult UL, not a target. | Very high 25(OH)D, high calcium, kidney injury, neuro-GI symptoms. | Clinical review notes guidelines generally agree 25(OH)D >150 ng/mL poses significant toxicity risk (toxicity review). |
| U-shaped mortality curve debate | Observational association, not a proven supplement side effect. | Possible risk signal at high serum levels; interpretation is debated because illness, testing behavior, and supplementation patterns can confound results. | Avoid chasing high-normal or supraphysiologic 25(OH)D without medical reason. | NIH summarizes National Academies concern about avoiding serum 25(OH)D above roughly 50–60 ng/mL and notes associations above 30–48 ng/mL in some outcomes (NIH ODS). |
| High intermittent bolus risk | Population-dependent; concerning in older adults. | Large infrequent doses may perform worse than daily/weekly dosing for falls/fractures and respiratory outcomes. | Do not self-prescribe monthly/annual megadoses for wellness. | Older-adult meta-analysis suggested avoiding high intermittent doses without known deficiency/osteoporosis status, and BMJ ARI analysis favored daily/weekly dosing without bolus doses (elderly fracture meta-analysis, BMJ). |
Text version of this infographic
Low vitamin D increases deficiency risk. Adequate vitamin D is the goal for bone and mineral metabolism. Excess vitamin D can cause hypercalcemia and related toxicity. The adult upper limit is 4,000 IU/day, and toxicity usually occurs with 25(OH)D above 150 ng/mL. The upper limit is a safety ceiling, not a wellness target.
All interactions
| Interacts with | Type | Severity | Mechanism | Action |
|---|---|---|---|---|
| Corticosteroids — prednisone, dexamethasone, long-term inhaled/systemic steroids | Drug lowers vitamin D/calcium effect | Monitor | Steroids can reduce calcium absorption and affect vitamin D metabolism; osteoporosis is a known corticosteroid complication (drug-vitamin D systematic review, Mayo Clinic). | Monitor 25(OH)D, calcium intake, and bone risk; supplement only as part of a clinician’s bone-protection plan. |
| Weight-loss drugs — orlistat / Xenical / Alli | Reduced absorption | Separate timing | Orlistat blocks fat absorption and can lower absorption of fat-soluble vitamins including vitamin D (NIH ODS, Mayo Clinic). | Take vitamin D/multivitamin at least 2 hours apart or at bedtime; monitor levels if long-term. |
| Bile acid sequestrants — cholestyramine, colestipol, colesevelam | Reduced absorption | Separate timing | These bind bile acids and reduce micelle formation needed for absorption of fat-soluble vitamins; Mayo specifically lists cholestyramine lowering vitamin D uptake (Mayo Clinic). | Separate vitamin D by at least 4 hours and monitor 25(OH)D if used chronically. |
| Anticonvulsants — phenytoin, phenobarbital, carbamazepine, primidone | Increased breakdown / deficiency risk | Monitor | Enzyme induction increases vitamin D catabolism and can reduce calcium absorption; Mayo lists phenobarbital and phenytoin as breaking down more vitamin D (drug-vitamin D systematic review, Mayo Clinic). | Check 25(OH)D and bone health periodically; dosing may need clinician adjustment. |
| Tuberculosis medicines — rifampin, isoniazid | Metabolism alteration | Monitor | Rifampin induces CYP3A4 and isoniazid inhibits CYP3A4; small time-series studies reported mixed 25(OH)D effects, so systematic review recommends monitoring rather than assuming a predictable effect (drug-vitamin D systematic review). | Monitor 25(OH)D and calcium during prolonged TB therapy; avoid high-dose D in granulomatous disease unless supervised. |
| Thiazide diuretics — hydrochlorothiazide, chlorthalidone, indapamide | Hypercalcemia risk | Use caution / monitor calcium | Thiazides decrease urinary calcium excretion while vitamin D increases calcium absorption, which can cause or worsen hypercalcemia (drug-vitamin D systematic review, Mayo Clinic). | Do not combine high-dose D/calcium with thiazides without checking serum calcium, especially in older adults, kidney disease, or hyperparathyroidism. |
| Calcium supplements — calcium carbonate, citrate, high-calcium antacids | Additive calcium load | Monitor | Vitamin D increases calcium absorption; combined calcium+D increased kidney stones in large evidence reviews (NIH ODS, USPSTF evidence review). | Use calcium only when diet is inadequate or prescribed; avoid exceeding total calcium needs. |
| Digoxin — Lanoxin | Hypercalcemia amplifies toxicity | Avoid high-dose D | High-dose vitamin D can cause hypercalcemia, and hypercalcemia increases risk of fatal heart rhythm problems with digoxin (Mayo Clinic). | Avoid high-dose vitamin D unless the prescriber is monitoring calcium and digoxin risk. |
| Aluminum-containing antacids / phosphate binders | Aluminum toxicity risk | Use caution / avoid in kidney failure | Vitamin D with aluminum-containing phosphate binders may cause harmful aluminum levels in people with kidney failure (Mayo Clinic). | Avoid chronic co-use in kidney disease unless prescribed and monitored. |
| Vitamin K antagonists — warfarin, acenocoumarol; relevant to D3+K2 products | K2 reduces anticoagulant effect | Avoid unsupervised K2 | Vitamin K2 can antagonize warfarin’s anticoagulant activity; PK/PD modeling found higher K2 doses lowered INR and required care (K2-warfarin study). | Do not start D3+K2 products on warfarin without anticoagulation-clinic approval. |
Who should avoid vitamin D or use it only medically
Avoid self-prescribed vitamin D, especially high-dose D, if you have hypercalcemia, kidney stones, advanced kidney disease, hyperparathyroidism, sarcoidosis, tuberculosis or other granulomatous disease, lymphoma, unexplained high calcium, or use calcitriol/alfacalcidol, thiazides, digoxin, or high-dose calcium (NIH Office of Dietary Supplements, toxicity review). People taking anticonvulsants, corticosteroids, rifampin/isoniazid, or fat-blocking drugs may need monitoring because these medicines can reduce vitamin D status or alter metabolism (drug-vitamin D systematic review).
Dosage and how to take it
The U.S. National Academies RDA for most adults through age 70 is 600 IU/day and for adults over 70 is 800 IU/day, while the adult upper limit is 4,000 IU/day (NIH Office of Dietary Supplements). ESCEO’s osteoporosis-focused guidance recommends 800–1,000 IU/day below 50 nmol/L / 20 ng/mL for older or postmenopausal bone-health contexts, while noting no clear general-population benefit above that threshold (ESCEO recommendations).
| Baseline 25(OH)D | Plain-language status | Typical action | Notes |
|---|---|---|---|
| <12 ng/mL / <30 nmol/L | Severe deficiency in many clinical frameworks | Medical evaluation; clinician may use short-term repletion doses and recheck labs. | Check calcium, kidney function, symptoms, medicines, malabsorption, and adherence. |
| 12–20 ng/mL / 30–50 nmol/L | Deficiency/insufficiency range depending on guideline | Often D3 800–2,000 IU/day or clinician-directed weekly dosing, then retest. | Daily or weekly regular dosing is usually preferable to large bolus wellness dosing. |
| 20–30 ng/mL / 50–75 nmol/L | Generally adequate for many bone-health frameworks; “insufficient” in some specialty targets | Maintain with diet, sun exposure, fortified foods, or modest D3 if risk factors persist. | Do not chase high levels without a reason. |
| 30–50 ng/mL / 75–125 nmol/L | Adequate/high-normal | Usually no escalation; avoid stacking multiple products. | NIH notes FNB advised avoiding levels above roughly 50–60 ng/mL. |
| >50–60 ng/mL / >125–150 nmol/L | Potentially excessive depending on context | Review supplements and calcium; consider clinician assessment. | Risk is higher with symptoms, high calcium, kidney disease, thiazides, or active vitamin D. |
Take D3 with a meal that contains fat, separate it from orlistat and bile acid sequestrants, and avoid stacking multivitamins, 60K sachets, calcium+D tablets, fortified drinks, and injections without counting total dose (NIH ODS, Mayo Clinic). If using D3+K2, avoid unsupervised use with warfarin because K2 can reduce anticoagulation effect (K2-warfarin study).
Text version of this infographic
| 25(OH)D result | Action |
|---|---|
| <12 ng/mL | Medical repletion; check calcium, kidney function, medicines, and cause. |
| 12–20 ng/mL | D3 often useful; prefer regular daily or weekly dosing and retesting. |
| 20–50 ng/mL | Maintain with food, sun, fortified foods, and modest D3 if risk factors persist. |
| >50 ng/mL | Review total intake and avoid escalation. |
Independent research, funding, and conflict review
Evidence relied on
| Source | Country | Evidence type | Funding source | Independence rating | Credibility | Likely motivation | How used |
|---|---|---|---|---|---|---|---|
| NIH Office of Dietary Supplements | United States | Government evidence fact sheet | U.S. federal government | Probably independent | Very strong | Public-health accuracy and institutional credibility. | Dose, UL, toxicity, interactions, status thresholds. |
| National Academies DRI report | United States | Consensus dietary-reference report | Government/academy process; exact funding not visible in fetched chapter | Probably independent | Very strong | Set conservative population reference intakes. | Calcium-vitamin D interdependence and UL context. |
| Tripkovic D2 vs D3 meta-analysis | United Kingdom | Systematic review/meta-analysis | MRC, UK Department of Health, BBSRC | Probably independent | Strong | Academic nutrition research and reproducible synthesis. | D3 vs D2 verdict. |
| Calcifediol vs cholecalciferol RCT | Spain | Randomized trial | Faes Farma | Conflicted | Moderate | Pharma product evidence generation. | Used cautiously for speed/potency, not as independent proof of superiority. |
| Liposomal D3 study | Poland | Clinical experiment + formulation study | University/National Centre grant plus Lipid Systems author ties | Conflicted | Moderate | Formulation development and commercial delivery-system validation. | Used only to say “promising, not settled.” |
| VITAL | United States | Large RCT | NIH; Pharmavite/Pronova/BASF donated agents; Quest testing support in full text | Conflicted but result-resistant | Very strong | Publicly funded prevention trial; in-kind product/testing support disclosed. | Null cancer and cardiovascular claims. |
| BMJ ARI IPD meta-analysis | United Kingdom | Individual participant data meta-analysis | NIHR Health Technology Assessment | Independent | Very strong | Public-health evidence synthesis under peer scrutiny. | Respiratory infection verdict. |
| D2d diabetes trial | United States | Randomized trial | NIDDK/NIH ODS/American Diabetes Association | Probably independent | Very strong | Public-health diabetes prevention research. | Diabetes verdict. |
| Drug-vitamin D interactions review | United States | Systematic review | Academic; specific funding not highlighted in fetched extract | Probably independent | Strong | Clinical nutrition safety synthesis. | Interaction mechanisms and monitoring advice. |
Evidence excluded or downgraded
| Evidence | Why downgraded |
|---|---|
| Commercial lab “vitamin D deficiency” pages | They sell tests, so their statements can overemphasize screening; used only for availability, price, and test logistics. |
| Supplement-brand D3+K2 and liposomal marketing | Product pages often cite mechanisms without hard outcomes and may use affiliate or direct sales incentives. |
| Observational low vitamin D studies | Low vitamin D can be a marker of illness, obesity, inflammation, indoor lifestyle, or low activity; RCTs are weighted more heavily for benefit claims. |
| High-dose injection/sachet anecdotes | Can correct labs but do not establish better clinical outcomes and may increase risk when used as unsupervised bolus therapy. |
Related research
For deeper, evidence-graded context on the conditions vitamin D is most often used for, see Pure City Research's condition guides:
- Type 2 diabetes: prevention and management guide
- Stress, anxiety & depression: prevention and management guide
Frequently Asked Questions
Is vitamin D3 better than vitamin D2?
Yes for most supplement users: D3 generally raises serum 25(OH)D more effectively than D2, especially when doses are given intermittently or as boluses (Tripkovic meta-analysis). D2 still works and can be useful for vegan or plant-source fortification, but lichen-derived D3 now makes vegan D3 possible.
What is the safest daily dose of vitamin D?
For adults, the RDA is 600 IU/day through age 70 and 800 IU/day above age 70, while the adult upper limit is 4,000 IU/day (NIH Office of Dietary Supplements). The right dose depends on baseline 25(OH)D, diet, sun exposure, body weight, medicines, and medical conditions.
Can Indians rely on sunlight alone for vitamin D?
Not always. An India-focused review argues that sun exposure is often inadequate because of clothing, social patterns, indoor lifestyle, and other barriers, despite abundant sunlight (India deficiency review). In India, a practical approach is safe sun exposure plus fortified foods and targeted supplementation/testing when risk is high.
Should vitamin D be taken with K2?
K2 is biologically plausible because vitamin K-dependent proteins help regulate calcium placement, and a meta-analysis found vitamin K plus D improved total BMD and undercarboxylated osteocalcin (K+D meta-analysis). It is optional, not mandatory, and people taking warfarin or other vitamin K antagonists should avoid D3+K2 unless their anticoagulation clinician approves it (K2-warfarin study).
Does vitamin D help depression or anxiety?
Large prevention evidence does not support vitamin D3 as a depression-prevention supplement: VITAL-DEP found no significant reduction in depression or clinically relevant depressive symptoms with 2,000 IU/day D3 (VITAL-DEP). Correcting a deficiency is still reasonable for general health, but vitamin D should not replace mental-health treatment.
Does vitamin D prevent colds or respiratory infections?
The evidence is mixed but more favorable than many other non-bone claims. A BMJ individual-participant meta-analysis found modest overall protection and the strongest effect in profound deficiency with daily or weekly dosing, not high-dose bolus dosing (BMJ).
Can vitamin D cause kidney stones?
Vitamin D alone at normal doses is less clearly linked to stones, but combined calcium plus vitamin D increased kidney stone risk in large evidence reviews (NIH Office of Dietary Supplements, USPSTF evidence review). People with prior stones should avoid high-dose vitamin D plus calcium unless monitored.
Is vitamin D useful for COVID-19?
Correct deficiency for general health, but vitamin D is not a proven COVID-19 treatment. Cochrane found insufficient and very uncertain evidence, while a later deficient-patient meta-analysis reported a possible but non-robust mortality signal and no clear benefit for ICU admission, ventilation, or hospital stay (Cochrane PubMed, 2025 meta-analysis).
Sources
- NIH Office of Dietary Supplements. Vitamin D — Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- National Academies / Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. https://www.nationalacademies.org/read/13050/chapter/7
- National Academies / Institute of Medicine. Tolerable Upper Intake Levels: Calcium and Vitamin D. https://www.ncbi.nlm.nih.gov/books/NBK56058/
- Tripkovic L, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status. https://pubmed.ncbi.nlm.nih.gov/22552031/
- Tripkovic L, et al. Daily supplementation with 15 μg vitamin D2 compared with vitamin D3 in South Asian and White European women. https://pubmed.ncbi.nlm.nih.gov/28679555/
- Lehmann U, et al. Bioavailability of vitamin D2 and D3 in healthy volunteers. https://pubmed.ncbi.nlm.nih.gov/24001747/
- Pérez-Castrillón JL, et al. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women. https://pubmed.ncbi.nlm.nih.gov/34101900/
- Cesareo R, et al. Calcifediol: Why, When, How Much? https://pmc.ncbi.nlm.nih.gov/articles/PMC10222038/
- Avenell A, et al. Cochrane: Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. https://www.cochrane.org/evidence/CD000227_vitamin-d-and-related-vitamin-d-compounds-preventing-fractures-resulting-osteoporosis-older-people
- Kahwati LC, et al. USPSTF evidence review: Vitamin D, Calcium, or Combined Supplementation for Primary Prevention of Fractures. https://pubmed.ncbi.nlm.nih.gov/29677308/
- Manson JE, et al. VITAL: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. https://pubmed.ncbi.nlm.nih.gov/30415629/
- VITAL full text with funding disclosures. https://pmc.ncbi.nlm.nih.gov/articles/PMC6425757/
- Okereke OI, et al. VITAL-DEP: Vitamin D3 and depression prevention. https://pubmed.ncbi.nlm.nih.gov/32749491/
- Martineau AR, et al. BMJ IPD meta-analysis: Vitamin D supplementation to prevent acute respiratory tract infections. https://www.bmj.com/content/356/bmj.i6583
- Pittas AG, et al. D2d: Vitamin D Supplementation and Prevention of Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/31173679/
- Cochrane. Vitamin D supplementation for prevention of mortality in adults. https://www.cochrane.org/evidence/CD007470_vitamin-d-supplementation-prevention-mortality-adults
- Stroehlein JK, et al. Cochrane living review: Vitamin D supplementation for treatment of COVID-19. https://pubmed.ncbi.nlm.nih.gov/34029377/
- 2025 meta-analysis: Vitamin D supplementation for managing COVID-19 in patients with vitamin D deficiency. https://pubmed.ncbi.nlm.nih.gov/40139702/
- Robien K, et al. Drug-vitamin D interactions: systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC5623087/
- Marcinowska-Suchowierska E, et al. Vitamin D Toxicity — A Clinical Perspective. https://pmc.ncbi.nlm.nih.gov/articles/PMC6158375/
- Nair R, Maseeh A. “Vitamin D: The sunshine vitamin” (J Pharmacol Pharmacother, 2012). https://pmc.ncbi.nlm.nih.gov/articles/PMC3942730/
- Jeyakumar A, et al. Vitamin D deficiency among adolescent girls in selected Indian states. https://pubmed.ncbi.nlm.nih.gov/30304971/
- Regulations compendium. <https://www.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.